MAXINE LEWIS: Open Payments
NPI 1649809831 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$596 in 22 payments from 13 companies in 2025. Trend: 2023 $76 · 2024 $229 · 2025 $596
Food & beverage: $596
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $85 |
| GlaxoSmithKline, LLC. | 3 | $84 |
| Daiichi Sankyo Inc. | 3 | $73 |
| AstraZeneca Pharmaceuticals LP | 2 | $54 |
| Merck Sharp & Dohme LLC | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Janssen Biotech, Inc. | 1 | $44 |
| PFIZER INC. | 1 | $34 |
| Gilead Sciences, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
Products named: KISQALI, KEYTRUDA, OJJAARA, Enhertu, RYBREVANT, IBRANCE, Trodelvy, BLENREP.
Industry payments across MD — which companies pay providers there.
